Keith L Davis

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib.

P. Paik, B. Cai, M. Price, 2023, Future oncology.

Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims data

Jeffery K. Allen, Keith L Davis, Heather M Edin, 2010, Movement disorders : official journal of the Movement Disorder Society.

Burden of Sliding Scale Insulin Use in Elderly Long‐Term Care Residents with Type 2 Diabetes Mellitus

J. Meyers, K. Davis, Wenhui Wei, 2013, Journal of the American Geriatrics Society.

Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib.

K. Davis, S. Iyer, J. Kaye, 2018, Current oncology.

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.

A. Mansfield, J. Neal, R. Heist, 2023, Clinical lung cancer.

Real‐world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease

D. Rubin, K. Davis, R. Mody, 2014, Alimentary pharmacology & therapeutics.